Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1727-1734

  Best, Simon R ^a   Ha, Patrick K ^a,b   Blanco, Ray G ^b   Saunders Jr , John R ^b   Zinreich, Eva S ^b   Levine, Marshall A ^b   Pai, Sara I ^a   Walker, Melissa ^b   Trachta, Jaclyn ^b   Ulmer, Karen ^b   Murakami, Peter ^c   Thompson, Richard ^c   Califano, Joseph A ^a,b   Messing, Barbara P ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

chemoradiation; oropharyngeal; pharyngoesophageal; squamous cell carcinoma; stricture

Indexed keywords

AMIFOSTINE; CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NECK DISSECTION; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; PHARYNGOESOPHAGEAL STRICTURE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; WART VIRUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; DOSE FRACTIONATION; ESOPHAGEAL STENOSIS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PHARYNGEAL DISEASES; RADIATION INJURIES; STOMATITIS;

EID: 81255149653     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21657     Document Type: Article

References (26)

1. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804. (Pubitemid 28277960)
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
3. Nguyen NP, Sallah S, Karlsson U, Antoine JE,. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer 2002; 94: 1131-1141. (Pubitemid 34150869)
4. Lee WT, Akst LM, Adelstein DJ, et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 2006; 28: 808-812. (Pubitemid 44320534)
5. Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 1110-1118.
6. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA,. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 76: 403-409.
7. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113 (10 Suppl): 2901-2909.
8. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269. (Pubitemid 351480538)
9. Vera-Llonch M, Oster G, Hagiwara M, Sonis S,. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2006; 106: 329-336. (Pubitemid 43100441)
10. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
11. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086. (Pubitemid 30019568)
12. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 2009; 38: 522-532.
13. Haddad R, Sonis S, Posner M, et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 2009; 115: 4514-4523.
14. Suntharalingam M, Jaboin J, Taylor R, et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 2004; 31 (6 Suppl 18): 2-7. (Pubitemid 40250136)
15. Worthington HV, Clarkson JE, Eden OB,. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007; 4: CD000978.
16. Barasch A, Epstein J, Tilashalski K,. Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics 2009; 3: 111-116.
17. Peterson DE, Barker NP, Akhmadullina LI, et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 2009; 27: 4333-4338.
18. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P,. Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 2001; 91: 1785-1790. (Pubitemid 32377965)
19. Lango MN, Egleston B, Ende K, et al. Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation. Head Neck 2010; 32: 341-347.
20. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956. (Pubitemid 46740304)
21. Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ,. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer 2009; 125: 2159-2165.
22. Sedaghat AR, Zhang Z, Begum S, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009; 119: 1542-1549.
23. Jo S, Juhasz A, Zhang K, et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009; 29: 1467-1474.
24. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
25. Grant DG, Hinni ML, Salassa JR, Perry WC, Hayden RE, Casler JD,. Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 2009; 135: 1225-1230.
26. Weinstein GS, O'Malley BW Jr, Snyder W, Sherman E, Quon H,. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133: 1220-1226. (Pubitemid 350294250)